Loading
QL2107 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
QL2107 is an investigational agent whose form is not stated in the registry developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 200mg on day 1 of each 21-day cycle of the study. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06754644 (A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC), in non-small-cell lung cancer. The largest, NCT06754644, plans to enrol 808 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.QL2107 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"QL2107" OR ABSTRACT:"QL2107") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about QL2107, not a curated reading list.
Shares A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors, A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm, Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors, Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.